NCT06796517Recruiting
Immunotherapy in Lymphoma
Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
Source: ClinicalTrials.gov · Last updated 28 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is: Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies? Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes. Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 72 (estimated)
- First submitted
- 19 Jan 2025
- Start date
- 26 Jun 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- Sung-Soo Park
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06796517
What you commit to
- Study type: Observational
- Planned participants: 72
- From 26 Jun 2024 to the primary completion date, Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)
Other
- Patients who have progressed to acute leukemia
- Patients who developed solid tumor during treatment
Who the study is looking for
- Adults aged 19 to 74 years.
- Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma
- Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma
Age in the registry: 19 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul St. Mary Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| Yeoido St. Mary Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.